Trial · NCT01425008
Adverse event totals57
The totals the trial posted for each group.
1 to 20 of 57
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | 1 | 4 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | 0 | 3 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | 1 | 3 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | 0 | 3 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | 0 | 7 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | 1 | 7 |
| Total, all-cause mortality | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | 0 | 3 |
| Total, all-cause mortality | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | 0 | 3 |
| Total, all-cause mortality | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | 2 | 13 |
| Total, all-cause mortality | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | 1 | 4 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | 0 | 16 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | 2 | 8 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | 2 | 16 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | 0 | 1 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | 0 | 6 |
| Total, all-cause mortality | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | 0 | 11 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | 1 | 20 |
| Total, all-cause mortality | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | 1 | 2 |
| Total, all-cause mortality | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | 0 | 19 |
| Total, other adverse events | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | 4 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01425008/event-totals